{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/entity/OTLK/timeline","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://api.morvs.ai/license","usage_info":"https://api.morvs.ai/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-10-16T02:36:01.907Z","methodology_url":"https://api.morvs.ai/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":11820,"canonical_name":"Outlook Therapeutics, Inc.","cik":"0001649989","uei":null,"lei":null,"duns":null,"ticker":"OTLK"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","dol.form5500"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":42},"count":42,"timeline":[{"ts":"2026-09-30","kind":"sec.filing","form_type":"8-K","title":"8-K — Outlook Therapeutics, Inc. — 2026-09-30","url_slug":"/sec/cik-0001649989/8-k/0001104659-26-112356","accession_number":"0001104659-26-112356","importance":35},{"ts":"2026-09-18","kind":"sec.filing","form_type":"8-K","title":"8-K — Outlook Therapeutics, Inc. — 2026-09-18","url_slug":"/sec/cik-0001649989/8-k/0001104659-26-108952","accession_number":"0001104659-26-108952","importance":35},{"ts":"2026-09-02","kind":"sec.filing","form_type":"3","title":"3 — Outlook Therapeutics, Inc. — 2026-09-02","url_slug":"/sec/cik-0001649989/3/0002074701-26-000003","accession_number":"0002074701-26-000003","importance":30},{"ts":"2026-09-02","kind":"sec.filing","form_type":"4","title":"4 — Outlook Therapeutics, Inc. — 2026-09-02","url_slug":"/sec/cik-0001649989/4/0002074701-26-000005","accession_number":"0002074701-26-000005","importance":30},{"ts":"2026-08-27","kind":"sec.filing","form_type":"8-K","title":"8-K — Outlook Therapeutics, Inc. — 2026-08-27","url_slug":"/sec/cik-0001649989/8-k/0001104659-26-102446","accession_number":"0001104659-26-102446","importance":35},{"ts":"2026-08-18","kind":"sec.filing","form_type":"10-Q","title":"10-Q — Outlook Therapeutics, Inc. — 2026-08-18","url_slug":"/sec/cik-0001649989/10-q/0001104659-26-098415","accession_number":"0001104659-26-098415","importance":45},{"ts":"2026-08-17","kind":"sec.filing","form_type":"NT 10-Q","title":"NT 10-Q — Outlook Therapeutics, Inc. — 2026-08-17","url_slug":"/sec/cik-0001649989/nt-10-q/0001104659-26-097838","accession_number":"0001104659-26-097838","importance":30},{"ts":"2026-08-14","kind":"sec.filing","form_type":"SCHEDULE 13D/A","title":"SCHEDULE 13D/A — Outlook Therapeutics, Inc. — 2026-08-14","url_slug":"/sec/cik-0001649989/schedule-13d-a/0000899140-26-000895","accession_number":"0000899140-26-000895","importance":70},{"ts":"2026-08-14","kind":"sec.filing","form_type":"8-K","title":"8-K — Outlook Therapeutics, Inc. — 2026-08-14","url_slug":"/sec/cik-0001649989/8-k/0001104659-26-096478","accession_number":"0001104659-26-096478","importance":35},{"ts":"2026-08-14","kind":"sec.filing","form_type":"8-K","title":"8-K — Outlook Therapeutics, Inc. — 2026-08-14","url_slug":"/sec/cik-0001649989/8-k/0001104659-26-096510","accession_number":"0001104659-26-096510","importance":35},{"ts":"2026-08-14","kind":"sec.filing","form_type":"4","title":"4 — Outlook Therapeutics, Inc. — 2026-08-14","url_slug":"/sec/cik-0001649989/4/0000899140-26-000894","accession_number":"0000899140-26-000894","importance":30},{"ts":"2026-08-14","kind":"sec.filing","form_type":"4","title":"4 — Outlook Therapeutics, Inc. — 2026-08-14","url_slug":"/sec/cik-0001649989/4/0001104659-26-097406","accession_number":"0001104659-26-097406","importance":30},{"ts":"2026-08-14","kind":"sec.filing","form_type":"424B5","title":"424B5 — Outlook Therapeutics, Inc. — 2026-08-14","url_slug":"/sec/cik-0001649989/424b5/0001104659-26-096504","accession_number":"0001104659-26-096504","importance":30},{"ts":"2026-08-12","kind":"sec.filing","form_type":"8-K","title":"8-K — Outlook Therapeutics, Inc. — 2026-08-12","url_slug":"/sec/cik-0001649989/8-k/0001104659-26-094848","accession_number":"0001104659-26-094848","importance":35},{"ts":"2026-08-12","kind":"sec.filing","form_type":"424B5","title":"424B5 — Outlook Therapeutics, Inc. — 2026-08-12","url_slug":"/sec/cik-0001649989/424b5/0001104659-26-094970","accession_number":"0001104659-26-094970","importance":30},{"ts":"2026-08-12","kind":"sec.insider.2525252","reporter":"Sukhtian Ghiath M.","title":null,"shares":2525252,"price_per_share":0.99,"usd_value":2499999,"security_title":"Common Stock","importance":17.49999948},{"ts":"2026-07-29","kind":"sec.insider.p","reporter":"Sukhtian Faisal Ghiath","title":null,"shares":95398,"price_per_share":1.0482,"usd_value":99996,"security_title":"Common Stock","importance":50.0999961836},{"ts":"2026-07-29","kind":"sec.filing","form_type":"4","title":"4 — Outlook Therapeutics, Inc. — 2026-07-29","url_slug":"/sec/cik-0001649989/4/0001649989-26-000008","accession_number":"0001649989-26-000008","importance":30},{"ts":"2026-07-24","kind":"sec.filing","form_type":"8-K","title":"8-K — Outlook Therapeutics, Inc. — 2026-07-24","url_slug":"/sec/cik-0001649989/8-k/0001104659-26-086406","accession_number":"0001104659-26-086406","importance":35},{"ts":"2026-07-24","kind":"sec.filing","form_type":"8-K","title":"8-K — Outlook Therapeutics, Inc. — 2026-07-24","url_slug":"/sec/cik-0001649989/8-k/0001104659-26-086685","accession_number":"0001104659-26-086685","importance":35},{"ts":"2026-07-23","kind":"sec.filing","form_type":"4","title":"4 — Outlook Therapeutics, Inc. — 2026-07-23","url_slug":"/sec/cik-0001649989/4/0001649989-26-000006","accession_number":"0001649989-26-000006","importance":30},{"ts":"2026-07-21","kind":"sec.filing","form_type":"424B3","title":"424B3 — Outlook Therapeutics, Inc. — 2026-07-21","url_slug":"/sec/cik-0001649989/424b3/0001104659-26-085430","accession_number":"0001104659-26-085430","importance":30},{"ts":"2026-07-21","kind":"sec.filing","form_type":"EFFECT","title":"EFFECT — Outlook Therapeutics, Inc. — 2026-07-21","url_slug":"/sec/cik-0001649989/effect/9999999995-26-002376","accession_number":"9999999995-26-002376","importance":30},{"ts":"2026-07-17","kind":"sec.filing","form_type":"S-3","title":"S-3 — Outlook Therapeutics, Inc. — 2026-07-17","url_slug":"/sec/cik-0001649989/s-3/0001104659-26-084621","accession_number":"0001104659-26-084621","importance":30},{"ts":"2026-07-16","kind":"sec.filing","form_type":"8-K","title":"8-K — Outlook Therapeutics, Inc. — 2026-07-16","url_slug":"/sec/cik-0001649989/8-k/0001104659-26-084242","accession_number":"0001104659-26-084242","importance":35},{"ts":"2026-07-10","kind":"sec.filing","form_type":"DEFA14A","title":"DEFA14A — Outlook Therapeutics, Inc. — 2026-07-10","url_slug":"/sec/cik-0001649989/defa14a/0001104659-26-082361","accession_number":"0001104659-26-082361","importance":30},{"ts":"2026-07-08","kind":"sec.filing","form_type":"DRS","title":"DRS — Outlook Therapeutics, Inc. — 2026-07-08","url_slug":"/sec/cik-0001649989/drs/0001104659-26-081849","accession_number":"0001104659-26-081849","importance":30},{"ts":"2026-06-26","kind":"sec.filing","form_type":"8-K","title":"8-K — Outlook Therapeutics, Inc. — 2026-06-26","url_slug":"/sec/cik-0001649989/8-k/0001104659-26-078337","accession_number":"0001104659-26-078337","importance":35},{"ts":"2026-06-16","kind":"sec.filing","form_type":"8-K","title":"8-K — Outlook Therapeutics, Inc. — 2026-06-16","url_slug":"/sec/cik-0001649989/8-k/0001104659-26-074346","accession_number":"0001104659-26-074346","importance":35},{"ts":"2026-06-03","kind":"sec.filing","form_type":"4","title":"4 — Outlook Therapeutics, Inc. — 2026-06-03","url_slug":"/sec/cik-0001649989/4/0001649989-26-000005","accession_number":"0001649989-26-000005","importance":30},{"ts":"2026-06-02","kind":"sec.insider.p","reporter":"Haddadin Yezan Munther","title":null,"shares":29000,"price_per_share":0.8326,"usd_value":24145,"security_title":"Common Stock","importance":50.0241454},{"ts":"2026-06-01","kind":"sec.filing","form_type":"SCHEDULE 13D/A","title":"SCHEDULE 13D/A — Outlook Therapeutics, Inc. — 2026-06-01","url_slug":"/sec/cik-0001649989/schedule-13d-a/0000899140-26-000621","accession_number":"0000899140-26-000621","importance":70},{"ts":"2026-06-01","kind":"sec.filing","form_type":"DEF 14A","title":"DEF 14A — Outlook Therapeutics, Inc. — 2026-06-01","url_slug":"/sec/cik-0001649989/def-14a/0001140361-26-023583","accession_number":"0001140361-26-023583","importance":40},{"ts":"2026-06-01","kind":"sec.filing","form_type":"8-K","title":"8-K — Outlook Therapeutics, Inc. — 2026-06-01","url_slug":"/sec/cik-0001649989/8-k/0001104659-26-068659","accession_number":"0001104659-26-068659","importance":35},{"ts":"2026-06-01","kind":"sec.filing","form_type":"4","title":"4 — Outlook Therapeutics, Inc. — 2026-06-01","url_slug":"/sec/cik-0001649989/4/0000899140-26-000620","accession_number":"0000899140-26-000620","importance":30},{"ts":"2026-06-01","kind":"sec.filing","form_type":"DEFA14A","title":"DEFA14A — Outlook Therapeutics, Inc. — 2026-06-01","url_slug":"/sec/cik-0001649989/defa14a/0001140361-26-023585","accession_number":"0001140361-26-023585","importance":30},{"ts":"2026-05-28","kind":"sec.insider.p","reporter":"Sukhtian Ghiath M.","title":null,"shares":8539709,"price_per_share":0.5855,"usd_value":5000000,"security_title":"Common Stock","importance":54.9999996195},{"ts":"2026-05-28","kind":"sec.insider.p","reporter":"GMS Ventures & Investments","title":null,"shares":8539709,"price_per_share":0.5855,"usd_value":5000000,"security_title":"Common Stock","importance":54.9999996195},{"ts":"2026-05-18","kind":"sec.filing","form_type":"8-K","title":"8-K — Outlook Therapeutics, Inc. — 2026-05-18","url_slug":"/sec/cik-0001649989/8-k/0001104659-26-062865","accession_number":"0001104659-26-062865","importance":35},{"ts":"2026-05-15","kind":"sec.filing","form_type":"10-Q","title":"10-Q — Outlook Therapeutics, Inc. — 2026-05-15","url_slug":"/sec/cik-0001649989/10-q/0001104659-26-062632","accession_number":"0001104659-26-062632","importance":45},{"ts":"2026-05-13","kind":"sec.filing","form_type":"8-K","title":"8-K — Outlook Therapeutics, Inc. — 2026-05-13","url_slug":"/sec/cik-0001649989/8-k/0001104659-26-060305","accession_number":"0001104659-26-060305","importance":35},{"ts":"2026-05-13","kind":"sec.filing","form_type":"424B5","title":"424B5 — Outlook Therapeutics, Inc. — 2026-05-13","url_slug":"/sec/cik-0001649989/424b5/0001104659-26-060374","accession_number":"0001104659-26-060374","importance":30}]}